Zennova has conducted research and development on a series of high barrier ophthalmic drugs by LiquiPuls®. One of the heavyweight products is expected to be approved and launched in the United States in 2023, marking the entry of Chinese pharmaceutical companies into the global advanced ranks in the field of ophthalmic drugs. According to the material thermodynamics phase equilibrium theory and the material diffusion theory, LiquiPuls® solves the monitoring problem of material distribution and migration in the micro environment perfectly. Through this technology, it can be widely applied to the development of 505b1 and 505b2 . The company has applied for multiple invention patents and new utility patents around the development, application, and technical protection of LiquiPuls® .
World's Leading Nano-Drug Delivery Platform LiquiPuls® + BioCarrier™
-
01.
PMD patented technology
Original technology platform in the United States, with a continuous development process of 20 years. Innovative technology d on the Balance theory of material thermodynamics, the theory of material diffusion, and the principle of pulsed microdialysis (PMD)
Solved the monitoring industry challenges of material distribution and migration in the micro environment
In both homogeneous and heterogeneous liquids, complex physical, biological, and physiological system environments can monitor the release, distribution, and migration of small molecule drugs and biological macromolecular preparations
Instant, accurate, reliable, and microscopic
-
02.
Microsphere coating technology
Combination formulas of different drugs
Combination formulas with different release mechanisms
This type of product has a large number, high market value, and a long lifespan Adderall ® Taking the series as an example, although patent protection has long expired, the sales in the US market last year were still $1.2 billion
-
03.
Slow and controlled release technology
Improving drug applicability - optimizing treatment outcomes,
There are a large number of such products with high market value
Tecfidera ® For example, the US market sales in the past 12 months were approximately $4 billion.
-
04.
Nanoparticle technology
Improving bioavailability and reducing individual differences in patients' impact on drug efficacy
Currently, there are only four nano oral formulations in the US market, with sales of approximately $400 million last year
There is a lot of room for Product development. We have technical reserves to develop new drug NDA d on this technology
-
05.
Optimize administration
Reduce mutual interference between drugs
Reducing the interference of human drug resistance on drug absorption
Due to the high technical difficulty of this type of product, there are not many options available. Developing new dosage forms d on this technology has significant market value
Colcrys alone ® For example, the sales volume in the US market is approximately $350 million
-
06.
Technology Platform BioCarieer™
Guiding the direction of bioavailability-enhancing designs: Improved bioavailability > 5 Times
Increased human brain tissue drug concentration > 10 Times
Drug absorption interferences: 0